High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robust companies. Whether it be a well-known tech stock or a risky small-cap, I believe diversification towards growth can add value to your current holdings. Below I’ve compiled a list of stocks with a bright future ahead.
GlycoMimetics, Inc. (NASDAQ:GLYC)
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Founded in 2003, and now run by Rachel King, the company employs 42 people and with the company’s market capitalisation at USD $832.69M, we can put it in the small-cap category.
Thinking of investing in GLYC? I recommend researching its fundamentals here.
Insperity, Inc. (NYSE:NSP)
Insperity, Inc. provides human resources (HR) and business solutions to enhance business performance for small and medium-sized businesses in the United States. Founded in 1986, and now led by CEO Paul Sarvadi, the company employs 2,900 people and with the market cap of USD $2.79B, it falls under the mid-cap group.
Extreme optimism for NSP, as market analysts projected an outstanding earnings growth rate of 22.28% for the stock, supported by a double-digit sales growth of 24.71%. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 64.70%. NSP’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Should you add NSP to your portfolio? Have a browse through its key fundamentals here.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. Started in 2004, and currently lead by John Thompson, the company now has 33 employees and with the stock’s market cap sitting at USD $32.41M, it comes under the small-cap stocks category.
Interested to learn more about ANTH? I recommend researching its fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.